MetaCap

Castle Biosciences (CSTL) vs Lumexa Imaging (LMRI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lumexa Imaging is the larger company by market cap ($1.37 billion vs $1.01 billion), about 1.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CSTL-13.46%LMRI-23.00%
+17%-25%-67%
Dec 11, 20251 yearNov 20, 2026
CSTL-14.94%LMRI-23.04%
+13%-26%-66%
Dec 8, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CSTL versus LMRI key metrics
MetricCSTLLMRI
Share price$32.86$14.26
Market cap$1.01B$1.37B
1-day change-1.63%+1.42%
YTD return-15.53%-22.92%
1-year return-13.25%—
5-year return-23.79%—
Forward P/E—15.18
EPS (TTM)$-0.76$-0.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$344.23M—
Revenue growth (YoY)+3.66%—
Net income (latest FY)$-24.16M—
Gross margin79.37%—
Operating margin-12.44%—
Net margin-7.02%—
52-week high$44.28$19.45
52-week low$17.72$6.45
Distance from 52-week high-25.79%-26.68%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+46.68%+31.70%
Average volume382.23K372.45K
Shares outstanding30.82M96.12M
Employees1,0485,000
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Castle Biosciences

CSTL stock →

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.

Health Care · Medical Specialities · 1,048 employees

About Lumexa Imaging

LMRI stock →

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States.

Health Care · Medical Specialities · 5,000 employees

CSTL vs LMRI FAQ

Which is bigger, Castle Biosciences or Lumexa Imaging?

Lumexa Imaging (LMRI) is larger, with a market capitalization of $1.37B compared with $1.01B for Castle Biosciences (CSTL).

Are Castle Biosciences and Lumexa Imaging in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons